National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 5361-5362 [2023-01685]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 18 / Friday, January 27, 2023 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: CMS HCPCS
Modification to Code Set Form; Use:
The Healthcare Common Procedure
Coding System (HCPCS) Level II code
set is one of the standard code sets used
for this purpose. The HCPCS Level II
code set, also referred to as alphanumeric codes, is a standardized coding
system that is used primarily to identify
items, supplies, and services not
included in the HCPCS Level I Current
Procedural Terminology (CPT®) codes,
such as ambulatory services and durable
medical equipment, prosthetics,
orthotics, and supplies when used in
the home or outpatient setting as well as
certain drugs and biologicals. Because
Medicare and other insurers cover a
variety of these services and supplies,
HCPCS Level II codes were established
for assignment by insurers to identify
items on claims. HCPCS Level II
classifies similar items or services that
are medical in nature into categories for
the purpose of efficient claims
processing. For each alpha-numeric
HCPCS code, there is descriptive
terminology that identifies a category of
like items.
As stated in 42 CFR Sec. 414.40(a)
CMS establishes uniform national
definitions of services, codes to
represent services, and payment
modifiers to the codes. The HCPCS code
set has been maintained and distributed
via modifications of codes, modifiers
and descriptions, as a direct result of
data received from applicants. Thus,
information collected in the application
is significant to code set maintenance.
The HCPCS code set maintenance is an
ongoing process, as changes are
implemented and updated quarterly (for
drug and biological products) and
VerDate Sep<11>2014
16:53 Jan 26, 2023
Jkt 259001
biannual (for non-drug and nonbiological items or services); therefore,
the process requires continual collection
of information from applicants on a
quarterly and bi-annual basis. As new
technology evolves and new devices,
drugs and supplies are introduced to the
market, applicants submit applications
to CMS requesting modifications to the
HCPCS Level II code set. Form Number:
CMS–10244 (OMB control number:
0938–1042); Frequency: Quarterly;
Affected Public: Private sector, Business
or other for-profit; Number of
Respondents: 250; Total Annual
Responses: 250; Total Annual Hours:
2,500. (For policy questions regarding
this collection contact Sundus Ashar at
410–786–0750.)
2. Type of Information Collection
Request: Extension of a currently
approved collection; Title of
Information Collection: Emergency
Ambulance Transports and Beneficiary
Signature; Use: The statutory authority
requiring a beneficiary’s signature on a
claim submitted by a provider is located
in section 1835(a) and in 1814(a) of the
Social Security Act (the Act), for Part B
and Part A services, respectively. The
authority requiring a beneficiary’s
signature for supplier claims is implicit
in sections 1842(b)(3)(B)(ii) and in
1848(g)(4) of the Act. Federal
regulations at 42 CFR 424.32(a)(3) state
that all claims must be signed by the
beneficiary or on behalf of the
Beneficiary (in accordance with 424.36).
Section 424.36(a) states that the
beneficiary’s signature is required on a
claim unless the beneficiary has died or
the provisions of 424.36(b), (c), or (d)
apply.
For emergency and nonemergency
ambulance transport services, where the
beneficiary is physically or mentally
incapable of signing the claim (and the
beneficiary’s authorized representative
is unavailable or unwilling to sign the
claim), that it is impractical and
infeasible to require an ambulance
provider or supplier to later locate the
beneficiary or the person authorized to
sign on behalf of the beneficiary, before
submitting the claim to Medicare for
payment. Therefore, an exception was
created to the beneficiary signature
requirement with respect to emergency
and nonemergency ambulance transport
services, where the beneficiary is
physically or mentally incapable of
signing the claim, and if certain
documentation requirements are met.
Thus, we added subsection (6) to
paragraph (b) of 42 CFR 424.36. The
information required in this ICR is
needed to help ensure that services were
in fact rendered and were rendered as
billed. Form Number: CMS–10242
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
5361
(OMB control number: 0938–1049);
Frequency: Occasionally; Affected
Public: Private sector, Business or other
for-profit, Not-for-profits institutions;
Number of Respondents: 10,233; Total
Annual Responses: 10,954,288; Total
Annual Hours: 912,492. (For policy
questions regarding this collection
contact Sabrina Teferi at 678–491–
0546.)
Dated: January 24, 2023.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2023–01718 Filed 1–26–23; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; Heart, Lung, and
Blood Program Project Study Section.
Date: March 17, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Melissa H. Nagelin, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 208–R,
Bethesda, MD 20892, (301) 827–7951,
nagelinmh2@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
E:\FR\FM\27JAN1.SGM
27JAN1
5362
Federal Register / Vol. 88, No. 18 / Friday, January 27, 2023 / Notices
Dated: January 23, 2023.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: January 23, 2023.
David W Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01685 Filed 1–26–23; 8:45 am]
[FR Doc. 2023–01684 Filed 1–26–23; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group, NHLBI
Mentored Patient-Oriented Research Study
Section.
Date: March 2–3, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6705 Rockledge Drive,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Stephanie Johnson Webb,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6705 Rockledge Drive, Room 208–
V, Bethesda, MD 20892, (301) 827–7992,
stephanie.webb@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood 1Diseases
and Resources Research, National Institutes
of Health, HHS)
khammond on DSKJM1Z7X2PROD with NOTICES
This
proposed information collection was
published in the Federal Register on
October 12, 2022 (Vol. 87, No. 196, P.
61609) and allowed 60 days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Cancer Institute
(NCI), National Institutes of Health
(NIH), may not conduct or sponsor, and
the respondent is not required to
respond to, an information collection
that has been extended, revised, or
implemented on or after October 1,
1995, unless it displays a currently valid
Office of Management and Budget
(OMB) control number.
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, NIH has
submitted to OMB a request for review
and approval of the information
collection listed below.
Proposed Collection: Generic
Clearance for the Collection of
Qualitative Feedback on Agency Service
Delivery (NCI), 0925–0642, Expiration
Date 03/31/2023, EXTENSION, National
Cancer Institute (NCI), National
Institutes of Health (NIH).
Need and Use of Information
Collection: This activity collects
qualitative customer and stakeholder
feedback efficiently and timely, per the
Administration’s commitment to
improving service delivery. This generic
provides information about the National
Cancer Institute’s customer or
stakeholder perceptions, experiences,
and expectations, provides an early
warning of service issues, or focuses on
areas where communication, training, or
operations changes might improve
product or service delivery. It also
allows feedback to contribute directly to
the improvement of program
management. Feedback collected under
this generic clearance provides valuable
information but will not yield data that
can be generalized to the overall
population.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
9,337 hours.
SUPPLEMENTARY INFORMATION:
Submission for OMB Review; 30-Day
Comment Request; Generic Clearance
for the Collection of Qualitative
Feedback on Agency Service Delivery
(NCI)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30 days of the date of this
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or using the
search function.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Diane Kreinbrink, Office of
Management Policy and Compliance,
National Cancer Institute, 9609 Medical
Center Drive, Bethesda, MD 20892–9760
or call non-toll-free number (240) 276–
5582 or Email your request, including
your address to: diane.kreinbrink@
nih.gov. Formal requests for additional
plans and instruments must be
requested in writing.
SUMMARY:
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Type of respondent
Surveys .............................................
Individuals ........................................
VerDate Sep<11>2014
16:53 Jan 26, 2023
Jkt 259001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
27,100
E:\FR\FM\27JAN1.SGM
1
27JAN1
Average
burden per
response
(in hours)
12/60
Total annual
burden hours
5,420
]]>Agencies
[Federal Register Volume 88, Number 18 (Friday, January 27, 2023)]
[Notices]
[Pages 5361-5362]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01685]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Heart, Lung, and Blood Initial Review Group;
Heart, Lung, and Blood Program Project Study Section.
Date: March 17, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6705 Rockledge Drive,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Melissa H. Nagelin, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 208-R, Bethesda, MD 20892, (301) 827-7951,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
[[Page 5362]]
Dated: January 23, 2023.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-01685 Filed 1-26-23; 8:45 am]
BILLING CODE 4140-01-P
